ERS Genomics & AlgenScribe Enter Into CRISPR/Cas9 Licensing Agreement

License allows AlgenScribe to expand its research and development activities using CRISPR/Cas9. DUBLIN and NICE, France, Sept. 5, 2023 /PRNewswire/ — ERS Genomics Limited (‘ERS’) is pleased to announce a new license agreement with AlgenScribe SAS (‘AlgenScribe’). This is a non-exclusive…

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.